Clinical studies have additionally shown an increase in circulating tumor-specific CD4+ and CD8+ T cells in hepatocellular carcinoma patients (HCC) at 4 weeks post-RFA treatment [15]. This evidence concerns the gene CD8A and hepatocellular carcinoma.